ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 12 Jul 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing polatuzumab vedotin on the Medication Assistance Fund (MAF) for treating patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for haematopoietic cell transplant due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness at the price proposed by the manufacturer.

Clinical indication, subsidy class and MediShield Life claim limit for polatuzumab vedotin are provided in the Annex.


Polatuzumab vedotin for treating relapsed or refractory DLBCL (12 Jul 22) Polatuzumab vedotin for treating relapsed or refractory DLBCL PES (12 Jul 22)